Highlights of weekly biotech stock moves

Amgen Inc. (NASDAQ:AMGN) gained $0.02 to $58.01 last week after CMS decided not to issue a National Coverage Determination (NCD) for erythropoiesis-stimulating agents (ESAs) to treat anemia in patients with chronic kidney disease (CKD). In the U.S., Amgen markets Aranesp darbepoetin alfa for cancer and renal indications and Epogen epoetin alfa for chronic renal failure.

Meda AB (SSE:MEDAA) lost SEK0.30 to SEK65.70 last week after FDA accepted for filing an NDA for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients aged 12 years and up. The PDUFA date for the application, which was submitted in April, was not disclosed...